Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy
October 3, 2007
PITTSBURGH, Pa., October 3, 2007--Knopp Neurosciences Inc. ("Knopp") announced that Cheryl Fossum Graham, M.D., F.C.P., has joined the company as senior vice president of regulatory and development strategy.
brings to Knopp
28 years of experience in public and commercial regulatory leadership, including senior positions with the Food and Drug Administration
and responsibility for global regulatory affairs at Pfizer Inc.
In her capacity at Knopp, Dr. Graham leads development strategy as well as safety and regulatory activities associated with KNS-760704, an orally administrated small molecule in development by Knopp for amyotrophic lateral sclerosis (ALS).
"Dr. Graham's experience, judgment, and track record for innovation bring tremendous benefits to Knopp," said Michael Bozik, M.D., president and chief executive officer.
Prior to joining Knopp, Dr. Graham spent six years in senior leadership positions at Pfizer Inc., including as senior vice president of Pfizer Global Research and Development and as director of worldwide regulatory affairs.
Previously she served as vice president of clinical and regulatory research at Quintiles Inc.
From 1979 to 1993, Dr. Graham held numerous positions with the U.S. Food and Drug Administration, including as acting director, deputy director and group leader in the Drug Marketing and Cardio-Renal Drug Products divisions of the FDA Center for Drug Evaluation and Research (CDER).
She also served as regulatory scientist at Hyman, Phelps & McNamara, a Washington, DC-based food and drug law firm.
She holds degrees in biology/chemistry, pharmacy, microbiology, and medicine from the University of New Mexico, where she earned Phi Beta Kappa Honors.